AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight

What Was Tested

This registered phase 3 trial tested Amycretin.

Participants will receive either NNC0487-0111, the treatment being tested, or placebo, a treatment with no active medicine.

Which treatment participants receive is decided by chance.

It had two arms (groups): NNC0487-0111 (experimental) and NNC0487-0111 Placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 400 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female (sex at birth). Age 18 years or above at the time of signing the informed consent. Diagnosed with T2D ≥ 180 days before screening. For participants with knee OA at screening (approximately 50 participants), the following inclusion criteria apply.

The full record lists 10 inclusion and 12 exclusion criteria; among the exclusions: history of type 1 or type 2 diabetes mellitus; for participants with t2d at screening, the following exclusion criteria apply in addition to criterion 1 (above):; known hypoglycaemic unawareness as indicated by the investigator according to clarke's questionnaire question 8.

How the Study Was Run

The set-up was randomized, parallel-group and quadruple-blind.

Because people in this Amycretin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Amycretin study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-09-07 with completion listed for 2029-02-05.

It ran at 26 sites in Japan (26).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Relative change in body weight (time frame: From baseline (week 0) to week 84).

It also tracked 1 secondary outcome, for example Change in waist circumference measured according to Japan society for the Study of Obesity (JASSO) guideline.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Amycretin in 400 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Amycretin compound page, all human trials.